These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18928657)

  • 1. Predictive value of neoadjuvant chemotherapy for the clinical utility of subsequently performed major cancer surgery.
    Markman M
    Curr Oncol Rep; 2008 Nov; 10(6):447-8. PubMed ID: 18928657
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy in epithelial ovarian cancer.
    Pignata S; Cannella L; Leopardo D; Pisano C; Bruni GS; Facchini G
    Cancer Lett; 2011 Apr; 303(2):73-83. PubMed ID: 21353386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reply to M. Mohiuddin et al.
    Dewdney A; Hawkes EA; Cunningham D
    J Clin Oncol; 2011 Jul; 29(19):2737-8. PubMed ID: 21850737
    [No Abstract]   [Full Text] [Related]  

  • 4. Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease.
    Ferron JG; Uzan C; Rey A; Gouy S; Pautier P; Lhommé C; Duvillard P; Morice P
    Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):101-5. PubMed ID: 19740592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection.
    Dizon DS
    Gynecol Oncol; 2017 Feb; 144(2):241-242. PubMed ID: 28062117
    [No Abstract]   [Full Text] [Related]  

  • 6. X chemotherapy, myth and realities.
    Thomas M; Pavithran K
    J Indian Med Assoc; 2005 Sep; 103(9):489-90, 492, 494. PubMed ID: 16493871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
    Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-grade serous ovarian cancer: a unique disease.
    Schmeler KM; Gershenson DM
    Curr Oncol Rep; 2008 Nov; 10(6):519-23. PubMed ID: 18928667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?
    Vergote I; Amant F; Leunen K
    Gynecol Oncol; 2010 Oct; 119(1):1-2. PubMed ID: 20833283
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions.
    Onda T; Yoshikawa H
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1053-67. PubMed ID: 21806329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer.
    Vergote I; Tropé CG; Amant F; Ehlen T; Reed NS; Casado A
    J Clin Oncol; 2011 Nov; 29(31):4076-8. PubMed ID: 21931032
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
    Khairallah AS; Genestie C; Auguste A; Leary A
    Int J Cancer; 2018 Jul; 143(1):8-15. PubMed ID: 29218796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists.
    Berchuck A
    J Clin Oncol; 2007 Aug; 25(23):3552; author reply 3557-8. PubMed ID: 17687164
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy is rarely the easy way out.
    Robinson WR
    J Clin Oncol; 2012 May; 30(13):1563; author reply 1563-4. PubMed ID: 22412132
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic drug monitoring in oncology: does it have a future?
    McMahon G; O'Connor R
    Bioanalysis; 2009 Jun; 1(3):507-11. PubMed ID: 21083145
    [No Abstract]   [Full Text] [Related]  

  • 16. Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives.
    Seifert G; Budach V; Keilholz U; Wust P; Eggert A; Ghadjar P
    Radiat Oncol; 2016 Apr; 11():65. PubMed ID: 27138749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between short-term response and long-term survival for cervical cancer patients undergoing neoadjuvant chemotherapy: a system review and meta-analysis.
    Kong SY; Huang K; Zeng C; Ma X; Wang S
    Sci Rep; 2018 Jan; 8(1):1545. PubMed ID: 29367687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer.
    Son JH; Chang K; Kong TW; Paek J; Chang SJ; Ryu HS
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1294-1301. PubMed ID: 29683235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
    Hall TR; Dizon DS
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):262-8. PubMed ID: 27166608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
    Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
    Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.